INDICATIONS AND USAGE
PADCEV is a Nectin-4-directed antibody and microtubule inhibitor conjugate indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor, and a platinum-containing chemotherapy in the neoadjuvant/adjuvant, locally advanced or metastatic setting.
This indication is approved under accelerated approval based on tumor response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.
DOSAGE FORMS & STRENGTHS
For Injection: 20 mg and 30 mg of enfortumab vedotin-ejfv as a lyophilized powder in a single-dose vial for reconstitution.
Manufactured By: Astellas Pharma US, Inc
Prescribing Information URL: Click Here
FDA approved Anti-Cancer medicine PADCEV (enfortumab vedotin-ejfv) for injection is available upon request. Get best retail price of PADCEV (enfortumab vedotin-ejfv) for injection from trusted online pharmacy. For emergency product orders call 8750295029 (Mr. Neeraj Nagpal) or For enquires email [email protected]. For advanced treatments in India, Medvitaz Pharma Solution can even help patient to discuss with Medical Oncologist .
In December 2019, enfortumab vedotin-ejfv was approved in the United States for the treatment of adult patients with locally advanced or metastatic urothelial cancer who had previously received a programmed cell death receptor-1 (PD-1) or programmed death ligand 1 (PD-L1) inhibitor and a platinum-containing chemotherapy.
Enfortumab vedotin was approved based on the results of a clinical trial that enrolled 125 patients with locally advanced or metastatic urothelial cancer who received prior treatment with a PD-1 or PD-L1 inhibitor and platinum-based chemotherapy. The overall response rate, reflecting the percentage of patients who had a certain amount of tumor shrinkage, was 44%, with 12% having a complete response and 32% having a partial response. The median duration of response was 7.6 months.
The application for enfortumab vedotin-ejfv was granted accelerated approval, priority review designation, and breakthrough therapy designation. The U.S. Food and Drug Administration (FDA) granted the approval of Padcev to Astellas Pharma US Inc.
You can order enfortumab vedotin-ejfv injection direct from Medvitaz Pharma Solutions if the drug has not been approved or is not available in your country. We help you to get genuine, affordable and assurance of delivery. To get best retail price/cost of enfortumab vedotin-ejfv injection for injection in India, Call 8750295029 or Email [email protected]. FDA approved drugs of Australia, Canada, EU, India, New Zealand, Singapore, Switzerland, Turkey & USA.
Head of Operations
The profound knowledge of more than 20 years in sales and marketing sector, he has been working dedicatedly and contributing to pharmaceuticals industry. He handles all operations over the country.
Contact us and we will reply as soon as possible!
MEDVITAZ is an initiative for helping end-users directly to get the right medicines and right medical treatments from the right source.
